Home > PJ (current issue) > Letters | Search

PJ Online homeThe Pharmaceutical Journal
Vol 275 No 7361 p163
6 August 2005

This article
Reprint   Photocopy

PDF 70K, Acrobat Reader

Letters

· Preregistration (2)
· Registration
· Adverse drug reactions
· Birdsgrove House


Letters to the Editor

Adverse drug reactions

Prolonged use of nitrous oxide and oxygen mixture

From Dr M. E. Brown, MRPharmS and Dr J. Hoodless

The purpose of this letter is to remind and alert clinical pharmacists about the potential adverse effects of the extended use of nitrous oxide and oxygen mixtures. Those pharmacists who work in hospitals and perhaps some community settings may consider it appropriate to draw this to the attention of prescribing medical practitioners.

Generally 50 per cent nitrous oxide and 50 per cent oxygen mixtures have a good safety record in short-term pain management. However, three reports of suspected adverse drug reactions received via the yellow card scheme alerted us to instances in hospitals where patients have experienced suspected ADRs. Those patients had received 50 per cent nitrous oxide and 50 per cent oxygen mixtures on a regular daily basis for extended periods of weeks or months (personal communication, Committee on Safety of Medicines). Unusually lengthy administration may be connected with ADRs which are reported in medical literature such as Doran et al.1

We realise that there may be exceptional reasons for extended use. However, the summary of product characteristics for Linde’s Equanox, for example, states that it should not be used for more than 24 hours without monitoring of peripheral blood for features of megaloblastic anaemia and leukopenia. Administration more frequently than every four days should be accompanied by routine blood tests for evidence of megaloblastic change in red cells and hypersegmentation of neutrophils. The patient information leaflet alerts patients that blood may be taken to check red and white blood cells.

The mechanism of the adverse drug reaction is that nitrous oxide inactivates vitamin B12. That is a co-factor in methionine synthesis. The result is interference with folate metabolism. Prolonged administration of nitrous oxide impairs methionine and DNA synthesis. Results include megaloblastic bone marrow changes and possibly myeloneuropathy and subacute combined degeneration. Patients starting with a pre-existing depletion of vitamin B12 stores such as strict vegetarians may be most at risk. Injection of vitamin B12 may be required.

Malcolm E. Brown
Judith Hoodless

Qualified persons
Linde Gas UK Ltd, Manchester

Reference

1. Doran M, Rassam SS, Jones LM, Underhill S. Toxicity after intermittent inhalation of nitrous oxide for analgesia. BMJ 2004;328:1364–5.

Send your letter to The Editor

Previous Topic (Registration)
Next Topic (Birdsgrove House)

Back to Top


©The Pharmaceutical Journal